Table 1.

Clinicopathologic Features for 153 Men in the Study^*

	PSA Failure		P
	Yes (n = 76)	No (n = 77)
Mean (SD) age at surgery (y)	59.2 (7.2)	58.5 (7.0)	.547†
Median (range) follow-up (d)	2,156 (35–4,612)	2,017 (398–4,198)	.817‡
Gleason score ≥7	59 (78)	46 (60)	.017§
American Joint Committee on Cancer stage ≥pT3	46 (61)	21 (27)	<.0001§
Positive margins	34 (45)	17 (22)	.003§
Median (range) preoperative PSA (ng/mL)	7.9 (2.0–77.6)	6.3 (1.0–737.0)	.026‡
Median (range) gland volume (mL)	37.7 (11.5–103.9)	35.3 (9.4–102.1)	.835‡
Mean (range) measured cancer area per patient (mm2)	444.1 (1.1–3,900.7)	192.7 (0.7–2,191.7)	<.0001‡

PSA, prostate-specific antigen.

^*Data are given as number (percentage) unless otherwise indicated.

^†t test.

^‡Wilcoxon rank sum test.

^§χ².